Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | GRN | P28799 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21515669 | 0.81 | APOBEC3A (0.49) | APOBEC3AAPOBEC3GPIK3CGPDE10AHTR2A | |
| SCHEMBL23806233 | 0.77 | APOBEC3A (0.45) | APOBEC3AAPOBEC3GPIK3CGPDE10AMGLL | |
| SCHEMBL7481484 | 0.77 | APOBEC3A (0.45) | APOBEC3AAPOBEC3GPIK3CGPDE10AMGLL | |
| SCHEMBL15935247 | 0.75 | APOBEC3A (0.54) | APOBEC3AAPOBEC3GGRNSORT1PIK3CG | |
| SCHEMBL9968614 | 0.75 | DYRK1A (0.44) | GRNSORT1 | |
| SCHEMBL5872612 | 0.74 | APOBEC3A (0.43) | APOBEC3AAPOBEC3G | |
| SCHEMBL24656101 | 0.71 | NR3C1 (0.47) | GRNSORT1PDE10A | |
| SCHEMBL21863369 | 0.71 | APOBEC3A (0.53) | APOBEC3AAPOBEC3GPIK3CGPDE10AHTR2A | |
| SCHEMBL4789376 | 0.71 | APOBEC3A (0.53) | APOBEC3AAPOBEC3GPIK3CGPDE10AHTR2A | |
| SCHEMBL2181213 | 0.71 | APOBEC3A (0.53) | APOBEC3AAPOBEC3GPIK3CGPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | APOBEC3A 4858/4885APOBEC3G 4866/4885GRN 2313/4885 |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | APOBEC3A 4858/4885APOBEC3G 4866/4885GRN 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.